Does ECULIZUMAB Cause Focal segmental glomerulosclerosis? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Focal segmental glomerulosclerosis have been filed in association with ECULIZUMAB (SOLIRIS). This represents 0.0% of all adverse event reports for ECULIZUMAB.
7
Reports of Focal segmental glomerulosclerosis with ECULIZUMAB
0.0%
of all ECULIZUMAB reports
0
Deaths
4
Hospitalizations
How Dangerous Is Focal segmental glomerulosclerosis From ECULIZUMAB?
Of the 7 reports, 4 (57.1%) required hospitalization.
Is Focal segmental glomerulosclerosis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ECULIZUMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does ECULIZUMAB Cause?
Fatigue (4,858)
Off label use (4,228)
Haemoglobin decreased (3,028)
Headache (2,699)
Death (2,221)
Pyrexia (1,948)
Dyspnoea (1,819)
Asthenia (1,732)
Drug ineffective (1,644)
Nausea (1,579)
What Other Drugs Cause Focal segmental glomerulosclerosis?
TACROLIMUS (339)
MYCOPHENOLATE MOFETIL (181)
PREDNISONE (173)
CYCLOSPORINE (96)
METHYLPREDNISOLONE (81)
PREDNISOLONE (73)
RITUXIMAB (73)
BASILIXIMAB (67)
OMEPRAZOLE (60)
LANSOPRAZOLE (55)
Which ECULIZUMAB Alternatives Have Lower Focal segmental glomerulosclerosis Risk?
ECULIZUMAB vs EDARAVONE
ECULIZUMAB vs EDETATE
ECULIZUMAB vs EDOXABAN
ECULIZUMAB vs EDOXABAN TOSILATE
ECULIZUMAB vs EFALIZUMAB